Page 33 - 《中国药科大学学报》2026年第1期

第 57 卷第 1 期 张 靖，等：基于 STING 激动剂抗体偶联药物的研究进展 27

Oncol, 2022, 40(16_suppl): TPS2690. ship study of benzothiophene oxobutanoic acid analogues lead-
[27] Drozdowski B, Arai K, Kim DS, et al. 1017 PSMA-E7766 ing to novel stimulator of interferon gene (STING) agonists[J].
ADC: harnessing targeted delivery of STING agonists for anti- Eur J Med Chem, 2022, 241: 114627.
tumor activity in prostate cancer[C]//Regular and Young Investi- [35] Lyon RP, Bovee TD, Doronina SO, et al. Reducing hydropho-
gator Award Abstracts. BMJ Publishing Group Ltd, 2024: bicity of homogeneous antibody-drug conjugates improves
A1138-A1138. pharmacokinetics and therapeutic index[J]. Nat Biotechnol,
[28] Thomas R, Zhang WH. Rethink of EGFR in cancer with its ki- 2015, 33(7): 733-735.
nase independent function on board[J]. Front Oncol, 2019, 9: [36] Tsuchikama K, Anami Y, Ha SYY, et al. Exploring the next
800. generation of antibody-drug conjugates[J]. Nat Rev Clin Oncol,
[29] Wu YT, Fang Y, Wei Q, et al. Tumor-targeted delivery of a 2024, 21(3): 203-223.
STING agonist improvescancer immunotherapy[J]. Proc Natl [37] Kumari S, Raj S, Babu MA, et al. Antibody-drug conjugates in
Acad Sci USA, 2022, 119(49): e2214278119. cancer therapy: innovations, challenges, and future directions[J].
[30] Song ZL, Wang XY, Zhang Y, et al. Structure-activity relation- Arch Pharm Res, 2024, 47(1): 40-65.
ship study of amidobenzimidazole analogues leading to potent [38] Fu C, Tong WW, Yu LF, et al. When will the immune-stimulat-
and systemically administrable stimulator of interferon gene ing antibody conjugates (ISACs) be transferred from bench to
(STING) agonists[J]. J Med Chem, 2021, 64(3): 1649-1669. bedside[J]. Pharmacol Res, 2024, 203: 107160.
[31] Liu X, Wang MJ, Yang MJ, et al. Structure-activity relation- [39] Zhang X, Ou C, Liu HY, et al. General and robust chemoenzy-
ship study of amidobenzimidazole derivatives as stimulator of matic method for glycan-mediated site-specific labeling and
interferon genes (STING) agonists[J]. Eur J Med Chem, 2023, conjugation of antibodies: facile synthesis of homogeneous anti-
246: 114943. body-drug conjugates[J]. ACS Chem Biol, 2021, 16(11): 2502-
[32] Bukhalid RA, Duvall JR, Lancaster K, et al. XMT-2056, a 2514.
HER2-directed STING agonist antibody-drug conjugate, in- [40] Hasan MM, Laws M, Jin PQ, et al. Factors influencing the
duces innate antitumor immune responses by acting on cancer choice of monoclonal antibodies for antibody-drug
cells and tumor-resident immune cells[J]. Clin Cancer Res, conjugates[J]. Drug Discov Today, 2022, 27(1): 354-361.
2025, 31(9): 1766-1782. [41] Chau CH, Steeg PS, Figg WD. Antibody-drug conjugates for
[33] Ye Y, Yang GQ, Wang HL, et al. Abstract 2923: JAB-X1800: a cancer[J]. Lancet, 2019, 394(10200): 793-804.
potent immunostimulatory antibody-drug conjugate (iADC) tar- [42] Ferraro E, Drago JZ, Modi SN. Implementing antibody-drug
geting CD73[J]. Cancer Res, 2023, 83(7_Supplement): 2923. conjugates (ADCs) in HER2-positive breast cancer: state of the
[34] Shen AC, Li XY, Zhang Y, et al. Structure-Activity relation- art and future directions[J]. Breast Cancer Res, 2021, 23(1): 84.